SUMMARY A microbiological assay for the measurement of methotrexate has been designed, using a chloramphenicol resistant mutant of Lactobacillus casei as the test organism. The method is simple, precise and inexpensive. Results are not significantly different from those obtained using a methotrexate radioassay kit employing a competitive protein binding technique. However, where patients are being treated with co-trimoxazole, the competitive protein binding technique is unsuitable for measuring methotrexate levels due to the cross reactivity of the binder. This is not a problem with the microbiological assay described here, which is able to measure methotrexate in the presence of large doses of trimethoprim.
Methotrexate, 4-amino-10 methyl pteroylglutamic acid, is a cytotoxic drug which has wide clinical use in the treatment of neoplastic disease. '-4 It is also considered a most effective agent in the treatment of severe psoriasis.5 Methotrexate achieves its cytotoxic effect by acting as a spurious substrate for dihydrofolate reductase which prevents the reduction of dihydrofolate to tetrahydrofolate.6 This in turn blocks the formation of 5, 10-methylene tetrahydrofolate and thus synthesis of thymidine and DNA. Recently there has been extensive use of high dose methotrexate therapy followed by rescue with 5-formyl tetrahydrofolate (folinic acid). This means that high concentrations of the drug can be attained with free intracellular methotrexate in the rapidly dividing tumour cells which ensures the maximum cytotoxic effect. 5-formyl tetrahydrofolate can be metabolised to 5, 10-methylene tetrahydrofolate without the need for dihydrofolate reductase and is therefore able to bypass the block.
The two most severe side effects of high dose methotrexate treatment are myelosuppression and renal failure which have been reported to have a 6% mortality.7 8 The use of high dose methotrexate requires careful monitoring of the patient's serum concentrations of the drug and a number of methods have been designed for this purpose.9- '3 One commonly used method is based on competitive protein binding,"2
Accepted for publication 1 June 1983 but this suffers from cross reactivity with drugs such as trimethoprim that bind strongly to the bacterial dihydrofolate reductase used in the assay. There are occasions when patients are treated with both methotrexate and trimethoprim (cotrimoxazole) and in these patients the competitive protein binding assay gives erroneous results. Although the manufacturers of the kit claim a cross reactivity of only 15%, in our hands the cross reactivity has been much higher than this.
We describe here a microbiological method for the measurement of methotrexate using a chloramphenicol resistant strain of Lactobacillus casei (ATCC 7469) as the test organism which is simple, precise and unaffected by the presence of trimethoprim.
Material and methods
The method is essentially a modification of the automated microbiological folate method described by Davis et 
ANTIBIOTICS
The sensitivity of the chloramphenicol resistant L casei was tested against a series of methotrexate control samples, to which, the following antibiotics were added at a concentration of 100 mg/l: cefotaxime, streptomycin, tetracycline, amoxycillin, benzylpenicillin and gentamicin. These samples were also tested by the isotopic assay. Aqueous solutions of the same antibiotics at concentrations of 10 mg/l were treated as unknown samples and assayed by the microbiological assay.
To one methotrexate control serum trimethoprim was added to a concentration of 4 mg/l and assayed by both methods.
Various concentrations of leucovorin were added to aqueous methotrexate solutions containing 10, 1 and 0*1 umol of methotrexate respectively. These were assayed by both methods. Table 3 .
The results of the methotrexate control samples to which the various antibiotics were added are listed in Table 4 . Aqueous solutions at concentrations of 10 mg/l of the antibiotics showed inhibition equivalent to <1 nmolI of methotrexate when assayed by the microbiological assay.
Methotrexate concentrations of 10 ,umol were shown to be unaffected by up to 250 mg/l of leucovorin in either method. Similarly neither method was affected by 100 mg/l of leucovorin with methotrexate concentrations of 1 ,mol, or 0*1 ,mol.
One sample was assayed 20 times in 5 different batches by the microbiological method. Results Table 2 Icke, Davis, Thom Both control sera containined 100 nnol/l methotrexate and in addition control sera B contained 4 mg/l trimethoprim.
ranged from 275-344 nmol/V, with a mean of 308.9, SD of 24*6 and coefficient of variation of 7-9%.
Discussion
The concurrent treatment with co-trimoxazole and methotrexate in some patients can create difficulties in monitoring methotrexate concentrations by protein binding methods. The cross reactivity of trimethoprim with the protein binding assay was found to be considerably greater than the 15% claimed by the manufacturer (Table 3) . Trimethoprim was added to a methotrexate control serum at a concentration of 4 mg/l. This concentration was used as it is representative of peak serum concentrations of trimethoprim found in patients receiving co-trimoxazole. An expected result of 100 nmol/l of methotrexate yielded a recovery of 96% by the microbiological assay and 924% by the protein binding assay. Serum from patients on both methotrexate and co-trimoxazole demonstrated similar discrepancies with the protein binding assay (Table 3) . Kits based on competitive binding for measuring methotrexate which use a dihydrofolate reductase derived from bacteria can be expected to give spuri- In the lower range results were marginally less than those obtained by the competitive protein binding assay (Figure) ; however there was no statistically significant difference between the means of a series of samples ( Table 2) .
The use of a chloramphenicol-resistant strain of L casei as the test organism, greatly simplified the procedure and had the advantage that aseptic manoeuvres were not necessary, which permits the use of automated diluting systems. The microbiological inhibition assay using L casei has been used in this laboratory for over three years.
It takes longer to obtain results using this method than the radioisotope dilution assay as overnight incubation is required. However, the microbiological assay has been shown to give valid results of methotrexate and unlike the radioisotope dilution assay is unaffected by the presence of trimethoprim. The test is cheap and can be run for approximately one sixth of the cost of the radioisotope dilution assay in our laboratory.
We wish to thank Dr JM Jackson for his advice and encouragement.
